The Journal of the American Medical Association has released new guidelines stating that anti-coagulant drug Xarelto should not be used in patients with chronic kidney disease (CKD) including end-stage CKD. Xarelto is a blood thinner used to prevent blood clots and strokes in certain patients, though multiple reports claim Xarelto could increase the risk of adverse events, including blood clots and stroke.
CKD is a disease that affects more than 500 million people worldwide. The kidney condition makes certain patients more susceptible to serious complications such as blood clots. However, CKD also makes patients more likely to suffer bleeding complications.
Xarelto has been found to potentially increase the risk of severe bleeding events, including internal hemorrhaging and bleeding out. Because the blood thinner does not have a natural antidote, doctors do not recommend using the drug in patients who may be predisposed to severe bleeding. Several Xarelto lawsuits allege that the drug caused severe complications from side effects, including hospitalization and death.